June. 25, 2020 |
|
Aug. 04, 2023 |
|
jRCTs051200029 |
A double-blind randomized phase II study of AHCC for patients with resectable / borderline resectable pancreatic cancer (Phase II study of AHCC for pancreatic cancer) |
|
A double-blind randomized phase II study of AHCC for patients with resectable / borderline resectable pancreatic cancer (Phase II study of AHCC for pancreatic cancer) |
Satoi Sohei |
||
Kansai Medical University Hospital |
||
2-5-1 Shin-machi, Hirakata-city, Osaka |
||
+81-72-804-0101 |
||
satoi@hirakata.kmu.ac.jp |
||
Hashimoto Daisuke |
||
Kansai Medical University Hospital |
||
2-5-1 Shin-machi, Hirakata-city, Osaka |
||
+81-72-804-0101 |
||
daisukeh007@gmail.com |
Recruiting |
June. 25, 2020 |
||
230 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
placebo control |
||
parallel assignment |
||
treatment purpose |
||
1. Histologically proven invasive ductal carcinoma of the pancreas (adenocarcinoma, adenosquamous carcinoma), resectable (R) or borderline resectable (BR-A, BR-V) in General Rules for the Study of Pancreatic Cancer (the 7th Edition) |
||
1. Unresectable pancreatic cancer (UP-M) due to distant metastasis (eg, distant lymph nodes, liver, peritoneal dissemination, lung, pleural dissemination, brain, and bone) in General Rules for the Study of Pancreatic Cancer (the 7th Edition) |
||
20age old over | ||
No limit | ||
Both |
||
Pancreatic cancer |
||
AHCC group: AHCC (1.0g, 3 times per day) is given daily and also continued during preoperative and adjuvant chemotherapy, until 2-years after operation. |
||
Pancreatic cancer |
||
2-year disease-free survival rate |
||
completion rate and dose intensity of preoperative chemotherapy; response rate of preoperative chemotherapy; decreasing rate of tumor marker (CA 19-9, CEA) during preoperative chemotherapy; entry rate, completion rate, and dose intensity of adjuvant chemotherapy; safety of the protocol therapy (adverse effect); 2-year overall survival rate; nutrition score at pre- and post preoperative chemotherapy, and pre- and post adjuvant chemotherapy such as neutrophil to lymphocyte ratio, prognostic nutrition index, C-reactive protein to albumin ratio, modified Glasgow prognostic score, platelet to lymphocyte ratio |
Wakayama Medical University Certified Review Board | |
811-1 Kimiidera, Wakayama, Wakayama Prefecture 641-8509, Japan, Wakayama | |
+81-73-441-0896 |
|
wa-rinri@wakayama-med.ac.jp | |
Approval | |
May. 21, 2020 |
No |
|
none |